Recent studies have shed light on the potential of medicinal cannabis in addressing various psychiatric conditions, while also raising questions about its impact on psychosis.

No Increased Risk of Psychosis in High-Risk Individuals

A 2023 study published in the journal "Psychiatry and Clinical Neurosciences" examined the association between cannabis use and psychosis in individuals already at clinical high risk. Surprisingly, the research found no significant link between cannabis use and the development of psychotic disorders in this high-risk group.

Promising Findings for Various Psychiatric Disorders

A 2020 systematic review published in "BMC Psychiatry" summarised existing research on the medical application of cannabis across various psychiatric disorders. This review highlighted encouraging evidence for the use of medicinal cannabis in treating a range of conditions, including:

• Social Anxiety: CBD, a non-psychoactive component of cannabis, showed potential in reducing social anxiety.
• Schizophrenia: While not a standalone treatment, cannabinoids may offer complementary benefits for schizophrenia patients.
• Insomnia: Medicinal cannabis, particularly a specific cannabinoid extract (ZTL-101), has shown promise in improving sleep quality and reducing insomnia symptoms.
• ADHD: Preliminary findings suggest potential benefits for treating ADHD with an oral cannabinoid/terpene combination.
• PTSD: Cannabis use has been associated with a reduction in PTSD symptoms and improved quality of life.

Download the full study here.